Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
TGS Q4 2025 Earnings Call - Bond-Funded Buildout Puts Perito Moreno Expansion and $2.9bn NGL Project on Fast Track
TGS reported a softer Q4 2025 profit but materially stronger liquidity after a $500 million, 10-year bond that closed oversubscribed and lifted cash to ARS 1,808 billion. The quarter shows two stories...
- TGS issued a $500 million, 10-year bond at an 8% yield in November, the deal was oversubscribed with an order book of $1.3 billion.
- Proceeds from the bond are financing roughly $780 million of CapEx tied to the Perito Moreno pipeline expansion plus final regulated pipeline tranches adding a combined 26 million cubic meters per day of capacity.
- Company cash rose by ARS 864 billion in Q4 to ARS 1,808 billion (about $1.25 billion at the official rate), driven mainly by the bond proceeds.
- +12 more takeaways
Turning Point Brands Fourth Quarter 2025 Earnings Call - White pouch surge forces front-loaded investment
Turning Point Brands closed 2025 on a clear inflection point, driven by a rapid ramp of Modern Oral white nicotine pouches. Consolidated revenue rose 29% to $121 million, with Modern Oral net revenue ...
- Revenue up 29% year-over-year to $121.0 million in Q4 2025, driven primarily by Modern Oral (white pouch) growth.
- Modern Oral net revenue was $41.3 million in Q4, a 266% year-over-year increase; Modern Oral gross sales rose 337% year-over-year.
- Company is initiating 2026 Modern Oral guidance: gross sales $220 million to $240 million, net sales $180 million to $190 million.
- +12 more takeaways
Xeris Biopharma Q4 2025 Earnings Call - Financial self-sustainability and 30%+ revenue growth guide for 2026
Xeris closed 2025 with a clean break from the financing treadmill, reporting full-year revenue of $291.8 million, adjusted EBITDA of $59.4 million and net income for the year. Management calls 2025 tr...
- Full-year 2025 revenue was $291.8 million, up 44% year-over-year; Q4 revenue was $85.8 million, up 43% y/y.
- Xeris reported adjusted EBITDA of $59.4 million for 2025 and delivered net income on a full-year basis for the first time.
- Management says Xeris achieved financial self-sustainability, enabling internal funding for the pipeline and commercial expansion.
- +15 more takeaways
Norwegian Cruise Line Holdings Q4 2025 Earnings Call - New CEO flags execution failures, trims 2026 yield outlook to flat
John Chidsey, who joined the board last year and became CEO in the last two weeks, laid out a blunt diagnosis: strategy is sound, execution is not. Q4 and full-year 2025 results showed healthy margin ...
- New CEO John Chidsey has been on the job only a few weeks, and his top priorities are fixing execution, driving accountability, reducing leverage, and improving return on invested capital.
- Q4 2025 net yields grew 3.8%, full-year 2025 net yields rose 2.4% versus prior year.
- Q4 Adjusted EBITDA was $564 million, full-year Adjusted EBITDA was $2.73 billion, up 11% year-over-year; Adjusted Operational EBITDA margin improved to 37.1% (+160 bps).
- +12 more takeaways
Compugen Q4 2025 Earnings Call - AstraZeneca Monetization Buys Runway into 2029 While Preserving Majority Royalties
Compugen used a small, strategic monetization of future rilvegostomig royalties to secure $65 million upfront from AstraZeneca, extending its cash runway into 2029 and adding a $25 million near-term m...
- Compugen monetized a small portion of future rilvegostomig royalties to AstraZeneca for $65 million upfront, extending cash runway into 2029 assuming no further cash inflows.
- Deal added a $25 million milestone tied to BLA acceptance, and increased total remaining milestones tied to rilvegostomig to up to $195 million from $170 million previously.
- Company retains the majority of its royalty interest in rilvegostomig, remaining eligible for mid-single-digit tiered royalties on future sales.
- +12 more takeaways
Yatsen Q4 and Full Year 2025 Earnings Call - Skincare-Led Recovery Narrows Losses, Non-GAAP Turnaround
Yatsen closed 2025 with a clear, R&D-fueled recovery: revenue returned to robust growth and profitability crept back into the picture, driven almost entirely by skincare. Q4 revenue rose 20.1% year ov...
- Total net revenues for Q4 2025 rose 20.1% year over year to RMB 1.38 billion, matching prior guidance and outpacing industry growth.
- Full-year 2025 revenue grew 26.7% to RMB 4.3 billion, reversing the 2024 decline and signaling a broader recovery in the business.
- Skincare was the engine, with Q4 skincare revenue up 51.9% year over year, and full-year skincare revenue up 63.5%; skincare accounted for 61.1% of Q4 revenues and 53% for the full year.
- +13 more takeaways
Smith+Nephew Q4 & FY2025 Earnings Call - Product-led growth, margin expansion and Integrity buy to accelerate shoulders
Smith+Nephew closed 2025 with a clean set of results: underlying revenue up 5.3%, trading margin expanded 160 basis points to 19.7%, and free cash flow jumped to $840 million, enabling a $500 million ...
- FY2025 underlying revenue grew 5.3%, with all three business units above 5%, and Q4 revenue of $1.7 billion up 6.2% underlying (4.5% on an average daily sales basis).
- Trading margin expanded 160 basis points to 19.7% for 2025, driven by price, revenue leverage and productivity; gross margin rose to 70.9%.
- Free cash flow surged to $840 million, up 52.5% year on year, enabling completion of a $500 million share buyback in H2 2025. Net debt finished at $2.76 billion with leverage around 1.7x.
- +12 more takeaways
Endeavour Silver Q4 2025 Earnings Call - Kolpa, Terronera drove 48% production jump; $350M convertible backs Pitarrilla advance
Endeavour closed a transformational 2025: Kolpa was acquired, Terronera reached commercial production in October, and the company raised $350 million via a convertible debt to fund Pitarrilla. Those m...
- 2025 was transformational: Kolpa acquired in May, Terronera reached commercial production October 1, and Bolanitos was sold (closed Jan 15).
- Production jumped to 11 million ounces silver equivalent in 2025, a 48% increase versus 2024, with Q4 output about 2 million ounces of silver and 14,000 ounces of gold (nearly 4 million silver equivalent ounces in Q4).
- Record 2025 revenue of $468 million, up 115% year-over-year; mine operating earnings were $83 million and mine operating cash flow before taxes was $156 million. Cash position at December 31 was $215 million.
- +12 more takeaways
Sunstone Hotel Investors Fourth Quarter 2025 Earnings Call - Andaz Miami Beach Momentum Boosts RevPAR, Board Reauthorizes $500M Buyback
Sunstone closed 2025 on a stronger-than-expected note, driven by resort outperformance and the late-year contribution from the newly renovated Andaz Miami Beach. Q4 total RevPAR grew 7.4% (12.5% inclu...
- Q4 2025 results beat expectations, with total RevPAR growth of 7.4% and 12.5% including Andaz Miami Beach.
- Andaz Miami Beach is the clear operational driver, contributing ~540 basis points to rooms RevPAR and ~510 basis points to total RevPAR in Q4; YTD occupancy above 80% at a mid-$500 rate and RevPAR near $475.
- Company issued full-year 2026 guidance: rooms RevPAR +4% to +7% (to $234-$241) and total RevPAR +3.5% to +6.5% (to $385-$396), with Andaz contributing ~400 basis points at the midpoint.
- +12 more takeaways
Delek Logistics Partners Q4 2025 Earnings Call - Record 2025 EBITDA, sour gas ramp is the hinge for 2026 upside
Delek Logistics closed 2025 with a full year record Adjusted EBITDA of $536 million and a record fourth quarter Adjusted EBITDA of approximately $142 million. Management is pitching 2026 EBITDA in a $...
- Delek Logistics reported record full year 2025 Adjusted EBITDA of $536 million, driven by acquisitions and operations across gas, crude, and water businesses.
- Fourth quarter Adjusted EBITDA was about $142 million, up from $114 million a year earlier and $6 million above the prior quarter record.
- Distributable cash flow as adjusted for Q4 was $73 million, with an adjusted DCF coverage ratio of approximately 1.22 times.
- +12 more takeaways